2020
Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
Cheng H, Luo G, Jin K, Fan Z, Huang Q, Gong Y, Xu J, Yu X, Liu C. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Cancer Medicine 2020, 9: 2153-2159. PMID: 32017404, PMCID: PMC7064028, DOI: 10.1002/cam4.2895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCD4 Lymphocyte CountCirculating Tumor DNADNA Mutational AnalysisFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMutationNeoplasm StagingPancreatic NeoplasmsPolymerase Chain ReactionPrognosisProto-Oncogene Proteins p21(ras)Retrospective StudiesTime FactorsT-Lymphocytes, RegulatoryConceptsCell-free circulating tumor DNAAdvanced pancreatic cancer patientsPancreatic cancer patientsCirculating regulatory T cellsCirculating T-cell subsetsCA19-9 levelsRegulatory T cellsKRAS mutation statusT cell subsetsTumor-node-metastasisCancer patientsMutation statusTumor DNAKRAS mutationsT cellsAssociated with extremely poor survivalRegulatory T cell levelsAdvanced pancreatic cancerLevels of TregsProportion of TregsAbnormal immune statusCirculating tumor DNAT cell levelsPredicted worse prognosisTumor-node-metastasis stage
2019
AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN
Fan Z, Cheng H, Jin K, Gong Y, Huang Q, Xu J, Ni Q, Yu X, Liu C, Luo G. AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN. World Journal Of Surgical Oncology 2019, 17: 137. PMID: 31387646, PMCID: PMC6685146, DOI: 10.1186/s12957-019-1682-9.Peer-Reviewed Original ResearchConceptsInvasive IPMNInvasive intraductal papillary mucinous neoplasmStage IB diseaseStage IIA diseaseHazard ratioEdition classificationIIA diseaseIB diseaseStaging classificationStaging systemEnd Results cancer registryIntraductal papillary mucinous neoplasmEdition staging systemPredictors of survivalAmerican Joint CommitteeCancer (AJCC) staging systemPapillary mucinous neoplasmConclusionsThe AJCCResectable tumorsAJCC stagingStage IIACancer RegistryTumor sizeMucinous neoplasmsResultsIn total
2018
Trajectories after first‐episode psychosis: Complement to ambiguous outcomes of long‐term antipsychotic treatment by exploring a few hidden cases
Liu C, Lin Y, Liu C, Hsieh M, Chien Y, Hwang T, Hwu H. Trajectories after first‐episode psychosis: Complement to ambiguous outcomes of long‐term antipsychotic treatment by exploring a few hidden cases. Early Intervention In Psychiatry 2018, 13: 895-901. PMID: 29927087, DOI: 10.1111/eip.12696.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisLong-term antipsychotic treatmentAntipsychotic treatmentRecurrence of psychotic symptomsCourse of chronic schizophreniaLow-dose antipsychoticsChronic schizophreniaDysthymic statesPsychotic symptomsDiagnostic stabilityWord lettersRemission criteriaPsychosisAmbiguous informationProbability of relapseCoping strategiesImpending relapseAmbiguous outcomesDiscontinued medicationAntipsychoticsPersonalized formulationsMedication adherencePsychosocial factorsEarly interventionGroup of patients
2011
Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience
Pan J, Oh S, Soldevila‐Pico C, Nelson D, Liu C. Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience. Clinical Transplantation 2011, 25: 164-170. PMID: 20156222, PMCID: PMC3480317, DOI: 10.1111/j.1399-0012.2010.01211.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCase-Control StudiesDNA, ViralFemaleFollow-Up StudiesGraft SurvivalHepatitis BHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B virusHumansImmunoenzyme TechniquesLiver TransplantationMaleMiddle AgedPolymerase Chain ReactionPrevalenceRetrospective StudiesSurvival RateTissue DonorsTransplantation, HomologousTreatment OutcomeVirus ActivationConceptsHepatitis B virusDetectable HBV DNAHBV DNALiver allograftsLow prevalenceDe novo hepatitis B.Serum HBV DNA levelsHepatitis B core antigenHepatitis B surface antigenHBV DNA levelsSingle-center experienceB core antigenLiver biopsy tissueB surface antigenViral protein expressionHBV serologySeronegative recipientsHBV infectionHepatitis B.Such prophylaxisPositive donorsCore antigenRetrospective studyB virusProphylaxis
2006
Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum
Winfield R, Hochwald S, Vogel S, Hemming A, Liu C, Cance W, Grobmyer S. Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum. The American Surgeon 2006, 72: 719-723. PMID: 16913316, DOI: 10.1177/000313480607200811.Peer-Reviewed Original ResearchConceptsDuodenal gastrointestinal stromal tumorGastrointestinal stromal tumorsSmall bowel gastrointestinal stromal tumorsGastric gastrointestinal stromal tumorsStromal tumorsPartial duodenal resectionHistory of neurofibromatosisPortion of duodenumDuodenal resectionGastrointestinal bleedingMedian sizeAdjuvant therapyCommon presentationComplete resectionRetrospective reviewSmall bowelRare tumorCase reportSingle institutionIncidental findingPatientsPancreaticoduodenectomyResectionTumorsDuodenum
2005
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
Firpi R, Zhu H, Morelli G, Abdelmalek M, Soldevila‐Pico C, Machicao V, Cabrera R, Reed A, Liu C, Nelson D. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplantation 2005, 12: 51-57. PMID: 16382464, DOI: 10.1002/lt.20532.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsSustained virological responseVirological responseTransplant recipientsCombination of cyclosporineInterferon-based therapyCombination of interferonEffect of cyclosporineDose-dependent mannerAnti-viral potentialLiver transplantationHistologic diseaseImmunosuppressive agentsViral clearanceHerpes simplexC virusAntiviral effectCyclosporine inhibitsCyclosporineTherapyViral replicationAntiviral activityTacrolimusInterferonReplicon system